EVAX Evaxion Biotech: Accounting Value per Share

Evaxion Biotech A/S (EVAX) develops personalized cancer treatments through its PIONEER system. Digital modeling reduces reagent consumption, supporting ESG principles. The EDEN and PIONEER platforms provide the company's technological edge. The equity per share clearly demonstrates the dynamics of net assets, with the current mark equal to 1.15.

Book value per share determines the net asset value of an organization available to the holder of a single security after all liabilities are settled, serving as the foundation for assessing the business's intrinsic value. By analyzing the historical book value per share, an investor can see the actual capital of Evaxion Biotech A/S, which is supported by the transparency of clinical trials and the efficient management of its AI platform in partnership with global big pharma.